| Literature DB >> 22573116 |
P Invernizzi1, M Ransom, S Raychaudhuri, R Kosoy, A Lleo, R Shigeta, A Franke, F Bossa, C I Amos, P K Gregersen, K A Siminovitch, D Cusi, P I W de Bakker, M Podda, M E Gershwin, M F Seldin.
Abstract
Susceptibility to primary biliary cirrhosis (PBC) is strongly associated with human leukocyte antigen (HLA)-region polymorphisms. To determine if associations can be explained by classical HLA determinants, we studied Italian, 676 cases and 1440 controls, genotyped with dense single-nucleotide polymorphisms (SNPs) for which classical HLA alleles and amino acids were imputed. Although previous genome-wide association studies and our results show stronger SNP associations near DQB1, we demonstrate that the HLA signals can be attributed to classical DRB1 and DPB1 genes. Strong support for the predominant role of DRB1 is provided by our conditional analyses. We also demonstrate an independent association of DPB1. Specific HLA-DRB1 genes (*08, *11 and *14) account for most of the DRB1 association signal. Consistent with previous studies, DRB1*08 (P=1.59 × 10(-11)) was the strongest predisposing allele, whereas DRB1*11 (P=1.42 × 10(-10)) was protective. Additionally, DRB1*14 and the DPB1 association (DPB1*03:01; P=9.18 × 10(-7)) were predisposing risk alleles. No signal was observed in the HLA class 1 or class 3 regions. These findings better define the association of PBC with HLA and specifically support the role of classical HLA-DRB1 and DPB1 genes and alleles in susceptibility to PBC.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22573116 PMCID: PMC3423484 DOI: 10.1038/gene.2012.17
Source DB: PubMed Journal: Genes Immun ISSN: 1466-4879 Impact factor: 2.676
Summary of Subject Genotyping Information
| GWAS | IC | GWAS- | IC-only | Both | Total | |
| Italian PBC Cases | 453 | 622 | 54 | 223 | 399 | 676 |
| Italian Controls | 1042 | 597 | 843 | 398 | 199 | 1440 |
| GWAS | IC | GWAS- | IC-only | Both | Total | |
| Number of SNPs | 1548 | 4885 | 604 | 3941 | 944 | 5489 |
| SNPs overlaping 1000 Genome reference | 1435 | 4386 | 595 | 3546 | 840 | 4981 |
| SNPs overlaping HLA reference | 648 | 1444 | 166 | 962 | 482 | 1610 |
Additional details on subject set genotyping is in Supplemental Table 1.
GWAS: Genotyped using Illumina platforms with >550K genome-wide association study (GWAS) SNPs. The samples included in previous GWAS study.
IC: Subjects genotyped using Immunochip (IC) array.
Subjects genotyped using both GWAS platform and Immunochip array
Number of SNPs within the region [chromosome 6 bps 28911802 – 33813043 (HG19 map)] used for analyses.
Number of SNPs genotyped in region that overlap the reference sets used for imputation.
Figure 1Analysis of the HLA region association signals in PBC
In each panel, the symbols show the strength of the association signal (ordinate) for the corresponding position (Mb, HG19) on chromosome 6 (abscissa). For panel A, the p value before conditioning is shown. For panels B-F the p values are shown after conditioning on the HLA determinant(s) indicated in the panel. The blue color coded symbols denotes the strongest associated marker with p value <10−6, and the other markers are color coded to indicate marker LD with the strongest associated marker: Markers with strong LD (r2 > 0.8) (red); moderate LD (r2 > 0.5) (orange), weak LD (r2 > 0.2) (yellow) and little or no LD (open symbols) are shown. The SNPs with the strongest associations were rs115721871 at bp 32653792 (panels A and D), rs9277558 at bp 33056711 (panels B and C), and rs9268668 at bp 32413889 (panel F).
Summary of Association Results and Conditioning Studies of HLA alleles in PBCa
| Marker/Amino | base pair | Allele 1 | Allele 2 | MAF | MAF | p-value | Odds | Cond. p- | Cond. p- | Cond. p- |
|---|---|---|---|---|---|---|---|---|---|---|
| rs115721871 | 32653792 | A | G | 0.17 | 0.08 | 9.8E-17 | 2.61 | 9.4E-02 | 1.3E-19 | 1.2E-01 |
| rs4246055 | 32592360 | C | T | 0.19 | 0.10 | 2.9E-16 | 2.47 | 2.1E-02 | 1.6E-19 | 2.8E-02 |
| rs114183935 | 32655730 | A | G | 0.59 | 0.43 | 8.1E-16 | 1.80 | 1.9E-02 | 1.2E-18 | 3.1E-02 |
| rs114432443 | 32652278 | T | C | 0.39 | 0.53 | 4.6E-15 | 0.55 | 2.3E-02 | 1.4E-17 | 2.8E-02 |
| rs116493712 | 32669767 | T | C | 0.57 | 0.46 | 1.1E-09 | 1.56 | 2.6E-01 | 5.2E-10 | 1.8E-01 |
| rs114796881 | 32664960 | A | G | 0.30 | 0.41 | 1.2E-09 | 0.63 | 3.9E-01 | 1.8E-10 | 3.7E-01 |
| rs114327274 | 32289594 | A | G | 0.24 | 0.17 | 4.1E-08 | 1.66 | 1.2E-01 | 1.9E-08 | 1.2E-01 |
| rs116348417 | 32389648 | A | G | 0.26 | 0.37 | 4.9E-08 | 0.66 | 5.2E-01 | 6.2E-11 | 5.7E-01 |
| HLA-DRB1*08 | 32552064 | SPEC | OTHER | 0.08 | 0.03 | 1.6E-11 | 3.22 | 1.0E+00 | 7.3E-13 | 1.0E+00 |
| HLA-DQB1*04:02 | 32631061 | SPEC | OTHER | 0.07 | 0.03 | 1.4E-10 | 3.16 | 6.8E-01 | 9.0E-12 | 4.5E-01 |
| HLA-DRB1*11 | 32552064 | SPEC | OTHER | 0.15 | 0.26 | 1.4E-10 | 0.55 | 1.0E+00 | 9.4E-13 | 8.3E-01 |
| HLA-DQA1*04:01 | 32608306 | SPEC | OTHER | 0.07 | 0.02 | 1.9E-10 | 0.32 | 6.5E-01 | 9.9E-12 | 5.0E-01 |
| HLA-DQB1*03:01 | 32631061 | SPEC | OTHER | 0.21 | 0.31 | 6.1E-09 | 0.61 | 8.9E-01 | 3.8E-10 | 4.5E-01 |
| HLA-DQB1*05:03 | 32631061 | SPEC | OTHER | 0.09 | 0.05 | 6.2E-07 | 2.14 | 7.6E-01 | 8.2E-09 | 1.0E+00 |
| HLA-DRB1*14 | 32552064 | SPEC | OTHER | 0.09 | 0.05 | 6.9E-07 | 2.12 | 1.0E+00 | 8.8E-09 | 1.0E+00 |
| HLA-DPB1*03:01 | 33049368 | DET | OTHER | 0.16 | 0.10 | 9.2E-07 | 1.78 | 4.2E-06 | 1.0E+00 | 1.0E+00 |
| DRB1-AA74 | 32551948 | OTHER | A | 0.43 | 0.31 | 1.2E-11 | 1.70 | 5.9E-01 | 3.2E-12 | 9.9E-01 |
| DRB1-AA74 | 32551948 | L | OTHER | 0.08 | 0.03 | 1.3E-11 | 3.23 | 2.9E-01 | 6.1E-13 | 2.0E-01 |
| DQA1-AA69 | 32609279 | T | OTHER | 0.08 | 0.03 | 2.7E-11 | 3.21 | 6.0E-01 | 8.5E-13 | 6.4E-01 |
| DRB1-AA58 | 32551996 | E | A | 0.15 | 0.26 | 1.5E-10 | 0.55 | 1.0E+00 | 9.4E-13 | 1.0E+00 |
This Table provides a summary of results before and after conditioning on particular HLA determinants and includes: 1) the top four imputed SNPs (rows 1–4); 2) top four genotyped SNPs (rows 5–8); 3) all classical HLA determinants with p-values < 10–6 (rows 9–16); and 4) the top four HLA amino acid (AA) associations (rows 17–20). P values after conditioning on particular HLA genes (see methods) are also shown. The p values were determined using SNPTEST V2 (see Patients and Methods) and used the genotype probabilities. A complete summary of strongly association markers is provided in Supplementary Table 1.
The SNP name, classical HLA determinant or AA is shown.
The position corresponding to the marker is shown (chromosomal base pair positions from HG19).
Allele 1 is the minor allele used for the analysis. For sequences designated with amino acid (AA) numbers the symbol refers to the allele symbol corresponds to standard AA nomenclature. Where the AA is compared with multiple other AAs, "Other" is used to represent all alternative AAs. The AA position includes the leader sequence (e.g. DRB1* position 104 is the same as AA position 74 without the leader sequence). Where HLA determinants are provided, the specificity is compared with not having the specificity (OTHER).
MAF: Minor allele frequencies were estimated from probabilities (SNPTEST V2).
p values before conditioning using population substructure and gender as covariates.
p value after conditioning on the allele(s) listed in the heading line.
Comparison of Residual Association Beta Estimates and Odds Ratios after Conditioning Studies
| All Markers | Association | Controlled | Controlled | Controlled | Controlled | Controlled | Controlled | Controlled |
|---|---|---|---|---|---|---|---|---|
| mean B estimate | 0.242 | 0.188 | 0.205 | 0.211 | 0.237 | 0.180 | 0.197 | 0.190 |
| mean change in beta estimate | Reference | −0.055 | −0.037 | −0.026 | −0.005 | −0.062 | −0.045 | −0.052 |
| mean OR | 1.274 | 1.207 | 1.228 | 1.234 | 1.268 | 1.197 | 1.218 | 1.209 |
| mean B estimate | 0.710 | 0.165 | 0.297 | 0.340 | 0.585 | 0.159 | 0.295 | 0.179 |
| mean change in beta estimate | Reference | −0.424 | −0.236 | −0.229 | −0.005 | −0.430 | −0.240 | −0.410 |
| mean OR | 2.03 | 1.18 | 1.35 | 1.41 | 1.79 | 1.17 | 1.34 | 1.20 |
All markers including SNPs (MHC region), classical HLA determinants and HLA Amino Acids.
The beta estimate, change in beta estimate and odds ratios from SNPTESTV2 score test (see methods).
Results after conditioning on the indicated HLA genes or alleles.
Results using only markers with p values < 5 × 10−8 in the initial association tests.
Conditioning on Specific HLA DRB1 and DPB1 Alleles
| Group | Marker/Amino | base pair | p-value | Cond. p- | Cond. p- | Cond. p- | Cond. p- |
|---|---|---|---|---|---|---|---|
| 1 | rs114991247 | 32583504 | 5.45E-13 | 3.96E-13 | 2.15E-18 | 3.75E-14 | |
| 1 | rs116240177 | 32561662 | 8.20E-13 | 1.17E-12 | 3.66E-18 | 4.29E-14 | |
| 1 | DRB1-AA74L | 32551948 | 1.33E-11 | 2.26E-11 | 3.67E-16 | 1.48E-12 | |
| 1 | HLA-DRB1*08 | 32552064 | 1.59E-11 | 2.73E-11 | 4.55E-16 | 1.77E-12 | |
| 1 | DQA1-AA69T | 32609279 | 2.75E-11 | 3.55E-11 | 5.99E-16 | 2.35E-12 | |
| 1 | HLA-DQB1*04:02 | 32631061 | 1.38E-10 | 1.86E-10 | 4.02E-15 | 1.63E-11 | |
| 1 | HLA-DQA1*04:01 | 32608306 | 1.90E-10 | 1.73E-10 | 5.55E-15 | 2.01E-11 | |
| 2 | rs9461776 | 32575735 | 3.02E-12 | 2.39E-14 | 9.62E-15 | 1.53E-15 | |
| 2 | rs115671039 | 32603212 | 1.98E-11 | 9.29E-13 | 5.22E-13 | 2.91E-14 | |
| 2 | HLA-DRB1*11 | 32552064 | 1.42E-10 | 1.34E-12 | 4.34E-13 | 9.25E-14 | |
| 2 | DRB1-AA58E | 32551996 | 1.45E-10 | 1.34E-12 | 4.38E-13 | 9.30E-14 | |
| 2 | DQB1-AA71T | 32632646 | 5.25E-10 | 3.65E-09 | 4.68E-10 | 1.69E-12 | |
| 2 | HLA-DQB1*03:01 | 32631061 | 6.10E-09 | 3.29E-10 | 3.95E-10 | 3.25E-11 | |
| 3 | rs380911 | 32209451 | 8.94E-09 | 1.36E-10 | 4.52E-06 | 5.26E-09 | |
| 3 | rs115240978 | 32672383 | 1.28E-08 | 1.30E-10 | 2.24E-06 | 8.16E-10 | |
| 3 | HLA-DQB1*05:03 | 32631061 | 6.21E-07 | 4.79E-09 | 5.13E-05 | 2.31E-08 | |
| 3 | HLA-DRB1*14 | 32552064 | 6.89E-07 | 5.29E-09 | 4.83E-05 | 2.46E-08 | |
| 3 | DRB1-AA57A | 32551999 | 6.90E-07 | 5.29E-09 | 4.82E-05 | 2.46E-08 | |
| 3 | DRB1-AA60H | 32551990 | 6.90E-07 | 5.29E-09 | 4.82E-05 | 2.46E-08 | |
| 4 | rs116751915 | 33052502 | 8.11E-09 | 9.21E-09 | 3.09E-06 | 1.76E-10 | |
| 4 | rs114761768 | 33050442 | 1.79E-08 | 3.09E-08 | 4.73E-06 | 4.90E-10 | |
| 4 | DPB1-AA76M | 33048662 | 6.13E-08 | 3.78E-07 | 2.11E-05 | 1.07E-08 | |
| 4 | DPB1-AA170I | 33052958 | 1.06E-07 | 2.61E-07 | 1.61E-05 | 3.21E-09 | |
| 4 | HLA-DPB1*03:01 | 33049368 | 9.18E-07 | 2.05E-06 | 1.01E-06 | 3.70E-09 |
The group corresponds to those markers that are successfully controlled by specific HLA alleles (p value after conditioning is >1 × 10–4. The bold highlighted p-values indicate the p-values used in the “group” assignment. For each group the following are shown in this abbreviated summary: i) the two SNPs with the strongest association in the group; ii) the two HLA amino acids (AA) with the strongest association; and iii) all classical HLA alleles with p <10–6 prior to conditioning. The p values were determined using SNPTEST V2 (see methods) and used the genotype probabilities. A more complete summary of strongly association markers is provided in Supplementary Table 2.
The SNP name, classical HLA determinant or AA is shown. For the AA the letter following the residue number provides the relevant AA.
The position corresponding to the marker is shown (chromosomal base pair positions from HG19).
p values after conditioning using population substructure and gender as covariates.
p value after conditioning (Cond) on the allele(s) listed in the heading line.
Cumulative Effect of Risk and Protective Classical HLA Alleles for PBC Susceptibility
| Category | Controls | Cases | Odds Ratio | p-value |
|---|---|---|---|---|
| RISK - PROTECTIVE =/< −2 | 177 (12.3) | 34 (5.0) | 0.38 | 5.87E-08 |
| RISK - PROTECTIVE =/< −1 | 682 (48.1) | 185 (27.4) | 0.50 | 2.03E-12 |
| RISK - PROTECTIVE = 0 | 522 (36.3) | 246 (36.4) | 1.00 | NS |
| RISK - PROTECTIVE =/> +1 | 226 (15.7) | 245 (36.2) | 3.05 | 6.94E-25 |
| RISK - PRPTECTIVE =/> 2 | 32 (2.2) | 72 (10.7) | 5.25 | 1.37E-15 |
This table shows the results of categorizing each participant based on the sum of the each risk allele (positive number) and each protective allele (negative number). The risk alleles are DRB1*08, DRB1*14 and DPB1*03:01. The protective alleles are DRB1*11 and DRB1*13. The alleles were determined from the most probable allele after imputation and haplotype analyses (see Methods).
The number of subjects that are in each category are shown together with the % of total controls (1440) or percent of cases (676).
The two tailed Fisher exact p value from contingency table analyses comparing cases and controls in each category.